WuXi Biologics Leads Trio of Profit Surprises, Signaling Rebound for China’s Drug Services Sector
After a challenging two-year slump, China’s pharmaceutical outsourcing industry is showing signs of a powerful comeback, and the WuXi group is at the heart of it. WuXi Biologics (2269.HK), the flagship biologics services provider under the WuXi umbrella, issued a profit alert on July 24 projecting a 56% surge in net profit for the first […]









